Healthcare industry

Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently introduce therapeutic genes into immune cells.

Article - 14/04/2021

Calling for quality seal for implants

Today's seniors are older and more active, which is why implants remain in the body longer and are subjected to greater strain than before. Improved surfaces are expected to ensure that the implants heal and integrate into the bone optimally. In an interview with BIOPRO, Dietmar Schaffarczyk, CEO of Konstanz-based stimOS GmbH, explains why a voluntary quality seal makes sense and gives consumers a better chance of recognising high-quality…

Evotec SE announced today the launch of beLAB2122 in the Rhine- Main-Neckar region to efficiently advance first-in-class therapeutic concepts into investable drug discovery projects. Mediated and supported by BioRN, Evotec’s newest BRIDGE brings together the European Molecular Biology Laboratory (“EMBL”), the German Cancer Research Center (“DKFZ”), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen.

Quantum Technology Ulm - 08/04/2021

Diamonds for life sciences innovations

The world's first commercial quantum computer,’IBM Q System One’, is now in operation in Ehningen near Stuttgart. This is a major leap forward in quantum technology in Germany. It marks the point at which conventional computers reach their limits. The University of Ulm is involved in three of six collaborative projects being funded by the Baden-Württemberg Ministry of Economic Affairs, Labour and Housing Construction.

CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on mRNA and Celonic Group, a premium biopharmaceutical Contract Development and Manufacturing Organization specializing in the development and production of Advanced Therapy Medicinal Products and mammalian cell line-expressed bio-therapeutics, announced their partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV.